ANAB ANAPTYSBIO, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1370053 · Fiscal year ends 06/30
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY107.7%
TTM net income YoY81.0%
TTM EPS YoY78.1%
Revenue 3-yr CAGR179.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin35.9%
Net margin-11.5%
FCF margin1.9%
EBITDA margin36.0%
Returns
ROE-114.6%
ROA-7.1%
ROIC (approx.)—
Asset turnover0.62x
Leverage & solvency
Liabilities / assets96.1%
Debt / equity0.00x
Current ratio7.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.17x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $234.60M | $91.28M | $17.16M | $10.29M | $63.17M |
| R&D expense | $135.97M | $163.84M | $132.28M | $88.80M | $98.50M |
| SG&A expense | $11.35M | $13.63M | $41.95M | $36.64M | $21.49M |
| Operating income | $226.90M | $66.15M | -$164.41M | -$115.15M | -$56.81M |
| Interest expense | — | — | — | — | $0 |
| Pretax income | $162.28M | $31.14M | -$163.62M | -$128.70M | -$57.80M |
| Income tax | $772,000 | $158,000 | -$4,000 | $24,000 | $0 |
| Net income | -$13.23M | -$145.23M | -$163.62M | -$128.72M | -$57.80M |
| EBITDA | $226.92M | $66.17M | -$163.76M | -$114.48M | -$56.20M |
| EPS (basic) | -0.46 | -5.12 | -6.08 | -4.57 | -2.11 |
| EPS (diluted) | -0.44 | -4.92 | -6.08 | -4.57 | -2.11 |
| Weighted avg. shares (diluted) | 30.23M | 29.54M | 26.92M | 28.16M | 27.43M |
| Balance sheet | |||||
| Cash & equivalents | $138.20M | $23.08M | $0 | $71.31M | $495.73M |
| Short-term investments | $73.44M | $262.29M | $354.94M | $369.93M | $52.37M |
| Receivables | $33.85M | $40.77M | $6.85M | $1.42M | $876,000 |
| Current assets | $350.25M | $431.88M | $406.83M | $447.20M | $553.88M |
| PP&E, net | $111,000 | $131,000 | $2.10M | $2.09M | $2.28M |
| Total assets | $364.39M | $483.83M | $452.39M | $610.38M | $643.07M |
| Current liabilities | $38.62M | $45.43M | $37.44M | $26.05M | $16.10M |
| Total liabilities | $327.19M | $412.97M | $364.29M | $348.28M | $286.64M |
| Shareholders' equity | $37.21M | $70.87M | $88.10M | $262.10M | $356.43M |
| Shares outstanding | 28.02M | 30.47M | 26.60M | 28.51M | 27.65M |
| Cash flow statement | |||||
| Operating cash flow | $19.70M | -$135.34M | -$120.80M | -$73.59M | -$45.92M |
| Capital expenditure | $87,000 | $358,000 | $807,000 | $358,000 | $1.37M |
| Free cash flow | $19.61M | -$135.69M | -$121.61M | -$73.95M | -$47.29M |
| Investing cash flow | $228.03M | $31.36M | $144.75M | -$394.85M | $38.84M |
| Financing cash flow | -$132.61M | $127.05M | -$59.30M | $44.02M | $252.30M |
| Depreciation & amortization | $20,000 | $20,000 | $652,000 | $675,000 | $619,000 |
| Stock-based compensation | $3.77M | $7.22M | $33.20M | $27.36M | $15.35M |
| Share buybacks | $68.63M | $456,000 | $50.00M | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.